Cutiss

Executive Summary

Cutiss is a Swiss late-stage clinical TechBio company pioneering the bioengineering of skin tissue therapeutics. Its lead product, denovoSkin, is a first-in-class personalized tissue therapy designed to transform skin surgery through automated, on-demand production of living skin at scale. Founded in 2017 and headquartered in Zurich, the company is currently in Phase 2 clinical development, positioning it as a unique player in the regenerative medicine space. The technology addresses the critical unmet need for effective skin grafts in burns, chronic wounds, and reconstructive surgery, offering a potential paradigm shift from conventional split-thickness grafts to lab-grown, patient-specific skin. With its proprietary platform, Cutiss aims to overcome key limitations of current treatments, such as donor site morbidity, limited graft availability, and lengthy healing times. The automated manufacturing process is designed to ensure consistent quality and scalability, potentially enabling wider access to advanced skin therapies. As a private company in late-stage trials, Cutiss represents a compelling investment opportunity in the intersection of tissue engineering and digital manufacturing, though it remains reliant on successful clinical outcomes and regulatory approvals to realize its commercial potential.

Upcoming Catalysts (preview)

• H2 2026Phase 2 clinical data readout for denovoSkin65% success
• 2026Series C financing round to support late-stage development and manufacturing scale-up70% success
• 2026Regulatory submission or meeting (FDA/EMA) for Phase 3 trial design80% success